The first BET bromodomain of BRD4 bound to compound 13 in a bivalent manner

Experimental Data Snapshot

  • Resolution: 1.48 Å
  • R-Value Free: 0.210 
  • R-Value Work: 0.179 
  • R-Value Observed: 0.181 

wwPDB Validation   3D Report Full Report

Ligand Structure Quality Assessment 

This is version 1.2 of the entry. See complete history


Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153).

Bradbury, R.H.Callis, R.Carr, G.R.Chen, H.Clark, E.Feron, L.Glossop, S.Graham, M.A.Hattersley, M.Jones, C.Lamont, S.G.Ouvry, G.Patel, A.Patel, J.Rabow, A.A.Roberts, C.A.Stokes, S.Stratton, N.Walker, G.E.Ward, L.Whalley, D.Whittaker, D.Wrigley, G.Waring, M.J.

(2016) J Med Chem 59: 7801-7817

  • DOI: https://doi.org/10.1021/acs.jmedchem.6b00070
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 

    Here we report the discovery and optimization of a series of bivalent bromodomain and extraterminal inhibitors. Starting with the observation of BRD4 activity of compounds from a previous program, the compounds were optimized for BRD4 potency and physical properties. The optimized compound from this campaign exhibited excellent pharmacokinetic profile and exhibited high potency in vitro and in vivo effecting c-Myc downregulation and tumor growth inhibition in xenograft studies. This compound was selected as the development candidate, AZD5153. The series showed enhanced potency as a result of bivalent binding and a clear correlation between BRD4 activity and cellular potency.

  • Organizational Affiliation

    AstraZeneca, Mereside , Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.

Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Bromodomain-containing protein 4
A, B
127Homo sapiensMutation(s): 0 
Gene Names: BRD4HUNK1
UniProt & NIH Common Fund Data Resources
Find proteins for O60885 (Homo sapiens)
Explore O60885 
Go to UniProtKB:  O60885
PHAROS:  O60885
GTEx:  ENSG00000141867 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupO60885
Sequence Annotations
  • Reference Sequence
Small Molecules
Binding Affinity Annotations 
IDSourceBinding Affinity
XNH BindingDB:  5KHM Ki: min: 5, max: 158 (nM) from 4 assay(s)
IC50: min: 5, max: 1600 (nM) from 5 assay(s)
Binding MOAD:  5KHM Ki: 5.01 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Resolution: 1.48 Å
  • R-Value Free: 0.210 
  • R-Value Work: 0.179 
  • R-Value Observed: 0.181 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 41.754α = 90
b = 59.769β = 90
c = 107.151γ = 90
Software Package:
Software NamePurpose
XDSdata reduction
Aimlessdata scaling

Structure Validation

View Full Validation Report

Ligand Structure Quality Assessment 

Entry History 

Deposition Data

  • Released Date: 2016-09-21 
  • Deposition Author(s): Patel, J.

Revision History  (Full details and data files)

  • Version 1.0: 2016-09-21
    Type: Initial release
  • Version 1.1: 2017-08-09
    Changes: Database references, Derived calculations
  • Version 1.2: 2023-09-27
    Changes: Data collection, Database references, Refinement description